Table of contents
- Key Takeaways
- What Is EBITDA Multiple Valuation?
- How Is EBITDA Normalised Before Applying a Multiple?
- What Are the Sector EBITDA Multiples in India (2026)?
- How Are Comparable Companies Selected?
- What Is the Private Company Discount and How Is It Applied?
- Trading Multiples vs. Transaction Multiples: Which to Use?
- When Is EBITDA Multiple Valuation Not Appropriate?
- When Is an IBBI Registered Valuer Required?
- How Does EBITDA Multiple Valuation Interact with DCF?
- What Are the Key Adjustments for India Specific Risks?
- Closing Summary
- Need EBITDA Multiple Valuation Support?
- Start Your EBITDA Valuation Today
- Frequently Asked Questions: EBITDA Multiple Valuation
Part of the M&A Valuation Cluster Supporting guide within Elite Valuation's M&A series. For the full framework, read: M&A Valuation in India: Complete Guide
EBITDA multiple valuation is the market approach method most commonly used in Indian M&A, private equity transactions, and regulatory valuations. It translates a company's operating earnings into enterprise value by applying a sector specific multiple derived from listed peers or comparable transactions.
The method appears deceptively straightforward. In practice, the quality of the multiple depends entirely on the quality of the comparable selection, the accuracy of EBITDA normalisation, and the valuer's understanding of sector specific risk factors. An incorrectly selected multiple of even 2x can mean a difference of crores in a mid size deal.
This guide covers how EBITDA multiples work, what sector benchmarks apply in India as of 2026, how to normalise EBITDA before applying a multiple, and when an IBBI registered valuer is required to sign off the valuation for regulatory purposes.
Key Takeaways
- EBITDA multiple valuation applies a sector specific EV/EBITDA multiple to normalised operating earnings to derive enterprise value.
- Indian sector multiples range from 6x to 8x for traditional manufacturing to 25x to 40x for high growth SaaS and tech companies.
- EBITDA must be normalised before a multiple is applied. One off items, related party distortions, and understated provisions must be removed.
- A private company discount of 20% to 35% is typically applied to listed company multiples for unlisted Indian businesses.
- An IBBI registered valuer is mandatory for valuations under the Companies Act 2013, FEMA, and SEBI regulations.
- The method is unreliable for startups with negative EBITDA. Revenue multiples or DCF are preferred in those cases.
- Multiple selection must be documented with comparable company analysis. Regulators and acquirers scrutinise this justification.
What Is EBITDA Multiple Valuation?
Definition: EBITDA Multiple Valuation
A market approach valuation method that estimates enterprise value by multiplying a company's normalised EBITDA by a sector derived EV/EBITDA multiple. The multiple is sourced from comparable listed companies (trading multiples) or precedent M&A transactions (transaction multiples).
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortisation. It represents operating cash generating capacity stripped of financing decisions and accounting policies, making it the most capital structure neutral profitability metric.
The multiple represents what the market is willing to pay per rupee of EBITDA in that sector. A technology company trading at 20x EBITDA means investors value the business at 20 times its annual operating earnings. The higher the multiple, the higher the growth expectations embedded in the price.
EBITDA Multiple Valuation: Enterprise Value Formula
Enterprise Value = Normalised EBITDA x Sector EV/EBITDA Multiple
Then:
Equity Value = Enterprise Value - Net Debt + Cash
Example: Manufacturing Company
Normalised EBITDA (FY25): Rs. 12.5 crore
Sector EV/EBITDA Multiple: 9x (mid tier manufacturing)
Enterprise Value: 12.5 x 9 = Rs. 112.5 crore
Less Net Debt: Rs. 18 crore
Equity Value: Rs. 94.5 crore
How Is EBITDA Normalised Before Applying a Multiple?
Applying a sector multiple to reported EBITDA without normalisation is one of the most common valuation errors in Indian M&A. Reported figures for unlisted companies frequently include items that overstate or understate sustainable earnings.
Normalisation adjusts reported EBITDA to reflect what the business would earn on a recurring, arm's length basis under a new owner. This adjusted figure is what the multiple should be applied to.
EBITDA Normalisation: Common Adjustments
Add back (upward adjustments):
- One off legal, restructuring, or dispute related costs
- Promoter salary above market rate charged to P&L
- Transaction advisory fees expensed in the current year
Deduct (downward adjustments):
- Revenue from related parties at above market pricing
- Understated gratuity, leave encashment, or bad debt provisions
- Non recurring government subsidies or one time grants
- Rent concessions or costs not borne by the entity at arm's length
EBITDA Normalisation: Step by Step Example
Adjusted EBITDA = Reported EBITDA +/- Normalisation Items
Reported EBITDA (FY25): Rs. 18.5 crore
Add one off legal settlement: + Rs. 1.2 crore
Less related party revenue (above market pricing): - Rs. 2.8 crore
Less understated gratuity provision: - Rs. 0.9 crore
Normalised EBITDA: Rs. 16.0 crore (basis for multiple application)/h5>
Red Flag
If a company's reported EBITDA includes 30% or more revenue from related parties at non arm's length pricing, the normalised EBITDA will be materially lower. This is a common issue in Indian family businesses and requires careful review during financial due diligence before any multiple is applied.
What Are the Sector EBITDA Multiples in India (2026)?
The table below provides reference EV/EBITDA multiple ranges for major Indian sectors as of June 2026. These are derived from listed company trading multiples and recent precedent M&A transactions. Actual multiples applied in formal valuations require current benchmarking and professional judgement by an IBBI registered valuer.
| Sector | EV/EBITDA Range | Driver of Multiple | Typical Discount for Unlisted |
|---|---|---|---|
| Technology / SaaS | 15x - 40x | Recurring revenue, growth rate | 25% - 35% |
| Pharmaceuticals | 12x - 22x | Pipeline, regulatory approvals | 20% - 30% |
| FMCG | 18x - 30x | Brand strength, distribution | 20% - 30% |
| Financial Services (NBFC) | 8x - 15x | AUM growth, credit quality | 20% - 30% |
| Infrastructure / EPC | 8x - 14x | Order book, government contracts | 20% - 25% |
| General Manufacturing | 6x - 12x | Capacity utilisation, margins | 20% - 30% |
| Specialty Chemicals | 10x - 18x | Import substitution, exports | 20% - 30% |
| Healthcare / Hospitals | 14x - 25x | Bed occupancy, ARPOB | 20% - 30% |
| Logistics & Warehousing | 10x - 18x | Asset base, e-commerce exposure | 20% - 25% |
| Education / EdTech | 8x - 20x | Student base, course diversification | 25% - 35% |
| Real Estate (Developer) | 8x - 15x | Land bank, pre-sales, cycle stage | 20% - 30% |
| Retail | 7x - 14x | Same-store growth, footprint | 20% - 30% |
Important Note on Multiple Ranges
These ranges reflect publicly available data from BSE/NSE listed companies and disclosed M&A transactions. For regulatory valuations (Companies Act, FEMA, SEBI), an IBBI registered valuer must independently derive the applicable multiple with documented comparable company analysis, not rely on reference ranges alone.
Need EBITDA Multiple Valuation Support?
IBBI registered valuers for M&A valuation, share transfer, and regulatory compliance across India.
How Are Comparable Companies Selected?
Multiple selection is the most judgement intensive step in EBITDA valuation. The quality of comparables directly determines the reliability of the output.
Comparable Company Selection: Criteria
A comparable company should match the target on as many of the following as possible:
- Industry and sub-sector: A generic "manufacturing" peer is insufficient for a specialty chemical company
- Revenue scale: Avoid comparing a Rs. 50 crore company to a Rs. 5,000 crore listed peer. Size premium distorts multiples
- Growth profile: High growth companies trade at premium multiples. Match growth trajectory
- EBITDA margin: Higher margin peers command higher multiples. Adjust if margins diverge significantly
- Geography of operations: Pan-India vs. regional companies may attract different market premiums
- Market liquidity: Highly liquid large cap comparables carry liquidity premium over unlisted targets
Minimum 5 comparables are required for a robust analysis. 8 to 10 is preferred for formal regulatory reports.
When listed Indian comparables are insufficient (thin market, niche sector), the valuer may supplement with global comparables adjusted for India specific country risk premiums or with precedent transaction multiples from disclosed Indian M&A deals.
What Is the Private Company Discount and How Is It Applied?
Listed company multiples incorporate a liquidity premium, which is the ability to buy and sell shares instantly at a transparent price. An unlisted private company does not offer this liquidity. The private company discount (also called discount for lack of marketability or DLOM) adjusts for this difference.
Definition: Private Company Discount (DLOM)
A percentage reduction applied to the multiple derived from listed comparable companies to reflect the illiquidity of unlisted private company shares. Standard range in Indian practice is 20% to 35%, depending on company size, shareholder base, and exit options available to investors.
The discount is applied to the multiple, not to the final enterprise value separately. A listed peer trading at 15x EBITDA with a 25% DLOM yields an applicable multiple of 11.25x for the unlisted target.
Factors that increase the discount include concentrated promoter shareholding with no secondary market, absence of a defined exit path, small revenue scale below Rs. 50 crore, and dependence on key man promoters. Factors that reduce it include institutional investor presence, documented succession plans, or an active M&A process underway.
Trading Multiples vs. Transaction Multiples: Which to Use?
Two datasets are available when deriving EBITDA multiples: current stock market prices of listed peers (trading multiples) and prices paid in historical M&A deals (transaction multiples). Both are valid, and each has a different application context.
| Attribute | Trading Multiples | Transaction Multiples |
|---|---|---|
| Data Source | BSE/NSE live prices | Disclosed M&A deal terms |
| Reflects | Minority stake market view | Control premium paid by acquirer |
| Includes Control Premium | No | Yes (typically 20% to 40% above trading) |
| Best Used For | Minority stake valuation, ESOP, FMV determination | M&A deal pricing, full acquisition valuation |
| Data Availability in India | Readily available for NSE/BSE listed companies | Limited. Most Indian M&A deal values are undisclosed |
| Staleness Risk | Low. Real time data | High. Deals may be 2 to 5 years old |
For most Indian regulatory valuations (share transfers, Section 62 allotments, FEMA pricing), trading multiples with a DLOM adjustment are the starting point. Transaction multiples are used to support or cross check in the context of full acquisitions.
When Is EBITDA Multiple Valuation Not Appropriate?
1. Startups with Negative EBITDA
Pre-profit companies with negative operating earnings cannot be valued using EBITDA multiples. Revenue multiples or DCF with terminal value are used instead, depending on the stage and investor expectations.
2. Highly Capital Intensive Businesses
Infrastructure, power, and heavy manufacturing companies require significant ongoing capex. EBITDA ignores capex, making EV/EBITDA a misleading metric. EV/EBIT or EV/EBITDA minus capex is more appropriate.
3. Financial Services Companies
Banks, NBFCs, and insurance companies have interest income as operating revenue. EBITDA is structurally inapplicable. Price to Book (P/B) or Price to AUM multiples are standard for these sectors.
4. Holding Companies and Conglomerates
Holding companies derive value from subsidiaries. A consolidated EBITDA multiple misses the sum of the parts value, particularly when subsidiaries operate in different sectors with different multiple profiles.
5. Companies with Highly Cyclical EBITDA
Commodity producers, real estate developers, and seasonal businesses may show distorted EBITDA in a single year. Trailing twelve month or normalised three year average EBITDA should be used, and even then, DCF may be more appropriate.
When Is an IBBI Registered Valuer Required?
EBITDA multiple valuation, when used for regulatory purposes in India, must be performed by or under the supervision of an IBBI registered valuer. The requirement is statutory, not a best practice recommendation.
IBBI Registered Valuer: Statutory Requirement
- Companies Act, Section 62(1)(c): FMV for share allotments and rights issues must be certified by an IBBI registered valuer
- Companies Act, Sections 230-232: Swap ratio for mergers and demergers requires IBBI registered valuer report for NCLT filing
- Foreign Exchange Management (Non-Debt Instruments) Rules, 2019: Cross border share transfers require FMV by an IBBI registered valuer (DCF or NAV as mandated, EBITDA multiple may supplement)
- SEBI ICDR Regulation 166A: Preferential allotments to acquirers in listed companies require IBBI registered valuer determination
- Insolvency proceedings (IBC): Asset and business valuation for resolution plans requires IBBI registered valuer
The IBBI registered valuer's report must document the multiple selection methodology, the list of comparable companies or transactions used, adjustments made, and the rationale for any discounts applied. Regulators and transaction counterparties scrutinise this documentation closely.
How Does EBITDA Multiple Valuation Interact with DCF?
In formal valuations, EBITDA multiple valuation and DCF are typically used together as cross checks rather than in isolation. This is consistent with IBBI guidelines and standard valuation practice in Indian M&A.
The DCF produces an intrinsic value based on projected free cash flows discounted at WACC. The EBITDA multiple method produces a market referenced value based on what comparable businesses are currently priced at. If both methods produce values within 10% to 15% of each other, the valuation is internally consistent. A large divergence signals a need to review assumptions in one or both methods.
Triangulation Practice
A well constructed valuation report will present the EBITDA multiple range as the primary cross check against DCF, then weight the two outputs depending on the reliability of projections (DCF heavy for companies with strong forecast visibility) versus the quality of market comparables (multiple heavy for sectors with deep listed company data). The final FMV is typically the weighted average or midpoint of the two approaches, with the weighting explained and justified in the report.
What Are the Key Adjustments for India Specific Risks?
Indian company EBITDA multiples often require adjustments beyond the standard DLOM to reflect country specific and company specific risk factors that global benchmark multiples do not capture.
| Risk Factor | Direction of Adjustment | Typical Range |
|---|---|---|
| Key Man Dependency (Promoter Driven) | Downward | 5% - 15% discount |
| Customer Concentration (>40% from Single Client) | Downward | 5% - 10% discount |
| Strong IP, Brand, or Proprietary Technology | Upward | 5% - 20% premium |
| Geographic Revenue Diversification | Upward | 3% - 10% premium |
| Regulatory Risk (Sector Under Investigation) | Downward | 10% - 25% discount |
| Strong Management Team with Defined Succession | Upward | 5% - 10% premium |
| Pending Litigation with Material Exposure | Downward | Case specific |
Start Your EBITDA Valuation Today
IBBI certified valuers for M&A valuation, regulatory compliance, and sector benchmarking across India.
Closing Summary
EBITDA multiple valuation is the most widely used market approach in Indian M&A and remains the primary cross check to DCF in regulatory valuation reports. Its reliability depends on three things done well: rigorous EBITDA normalisation that reflects sustainable, arm's length earnings, disciplined comparable company selection with documented screening criteria, and an appropriately calibrated private company discount. The sector benchmarks in this guide provide a reference framework, but every formal valuation for regulatory purposes, whether under the Companies Act, FEMA, or SEBI, requires an IBBI registered valuer to independently derive and justify the applicable multiple. The valuation is only as defensible as the analysis behind the number.
Frequently Asked Questions: EBITDA Multiple Valuation
CA Sagar Shah, Founder
Mr Sagar Shah is the Founder of Elite Valuation and leads the firm’s Valuation and Advisory practice. With over 15+ years of professional experience.
Published Insights
